Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9008162 | 0.88 | SIGMAR1 (0.48) | SIGMAR1LDHACA2ALOX15ALOX12 | |
| SCHEMBL14747858 | 0.88 | TAS1R3 (0.43) | SIGMAR1ALOX15ALOX12 | |
| SCHEMBL9008224 | 0.88 | LDHA (0.51) | SIGMAR1LDHACA2ALOX15ALOX12 | |
| SCHEMBL12961274 | 0.88 | SIGMAR1 (0.43) | SIGMAR1LDHA | |
| SCHEMBL28924860 | 0.81 | SIGMAR1 (0.50) | SIGMAR1LDHACA2ALOX15ALOX12 | |
| SCHEMBL9008197 | 0.81 | LDHA (0.45) | SIGMAR1LDHACA2ALOX15ALOX12 | |
| SCHEMBL1911890 | 0.81 | SIGMAR1 (0.45) | SIGMAR1LDHACA2ALOX15ALOX12 | |
| SCHEMBL14747860 | 0.81 | TAS1R3 (0.47) | SIGMAR1LDHACA2ALOX15ALOX12 | |
| SCHEMBL8777046 | 0.78 | ATM (0.55) | SIGMAR1CA2STAT3KDM4EATM | |
| SCHEMBL16930229 | 0.78 | SIGMAR1 (0.69) | SIGMAR1LDHACA2ALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826350-B2 | Proline-based neuropeptide FF receptor modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2023-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11826350-B2 | Proline-based neuropeptide FF receptor modulators | NPFFR1, NPFFR2, NPBWR1 | SIGMAR1 183/4885LDHA 4661/4885CA2 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.